Cellular Biomedicine Group Inc., of Shanghai, appointed Scott J. Antonia and Guoping Fan to its new scientific advisory board. Antonia will advise the company on immuno-oncology and Fan will advise on stem cell technology and its applications.

Twi Pharmaceuticals Inc., of Taipei, Taiwan, appointed Jianbo Xie chief operating officer. Xie will be responsible for his existing R&D function, as well as production in Chungli and operations in Neihu headquarters. He was formerly R&D executive vice president.